Tackling the anterior nares and other sites of colonization: Implications for the dermatologist

Cutis

Volumn 79, Issue 6 SUPPL., 2007, Pages 52-59

  Del Rosso, James Q ^{a,b,c,e,f,g,h,i,j,k,l,m}   Elston, Dirk M ^d  

^a UNIVERSITY OF NEVADA   (United States)

^b TOURO UNIVERSITY NEVADA   (United States)

^c VALLEY HOSPITAL MEDICAL CENTER   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e Managed Care and Professional Affairs   (United States)

^f Coria Laboratories Ltd ^*  (Spain)

^g Galderma

^h Intendis Inc

ⁱ Johnson and Johnson ^*  (United States)

^j Medicis Pharmaceutical Corporation   (United States)

^k QLT Inc   (United States)

^l Ranbaxy Laboratories Limited   (India)

^m Stiefel Laboratories Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TOPICAL ANTIINFECTIVE AGENT;

ARTICLE; DRUG EFFECT; HETEROZYGOTE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; NOSE MUCOSA; PENICILLIN RESISTANCE; PREVALENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS, LOCAL; CARRIER STATE; HUMANS; METHICILLIN RESISTANCE; NASAL MUCOSA; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 34547495487     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751-762.
2. Kluytmans J, va Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997;10:505-520.
3. Eriksen NH, Espersen F, Rosdahl VT, et al. Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect. 1995;115: 51-60.
4. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule". Clin Infect Dis. 2004;39:806-811.
5. Hu L, Umeda A, Kondo S, et al. Typing of Staphylococcus aureus colonising human nasal carriers by pulse-field gel electrophoresis. J Med Microbiol. 1995;42: 127-132.
6. Squier C, Rihs JD, Risa KJ, et al. Staphylococcus aureus rectal carriage and its association with infections in patients in a surgical intensive care unit and a liver transplant unit. Infect Control Hosp Epidemiol. 2002;23: 495-501.
7. Mainous AF 3rd, Hueston WJ, Everett CJ, et al. Nasal carriage of Staphylococcus aureus and methicillin-resistant S aureus in the United States, 2001-2002. Ann Fam Med. 2006;4:132-137.
8. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis. 2006;193: 172-179.
9. Creech CB 2nd, Kernodle DS, Alsentzer A, et al. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J. 2005;24:617-621.
10. Nakamura MM, Rohling KL, Shashaty M, et al. Prevalence of methicillin-resistant Staphylococcus aureus nasal carriage in the community pediatric population. Pediatr Infect Dis J. 2002;21: 917-922.
11. Ellis MW, Hospenthal DR, Dooley DP, et al. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis. 2004;39:971-979.
12. Nouwen J, Boelens H, van Belkum A, et al. Human factor in Staphylococcus aureus nasal carriage. Infect Immun. 2004;72:6685-6688.
13. Aly R, Maibach HI, Shinefield HR. Microbial flora of atopic dermatitis. Arch Dermatol. 1977;113: 780-782.
14. Gilani SJ, Gonzalez M, Hussain I, et al. Staphylococcus aureus re-colonization in atopic dermatitis: beyond the skin. Clin Exp Dermatol. 2005;30:10-13.
15. Hon KL, Lam MC, Leung TF, et al. Clinical features associated with nasal Staphylococcus aureus colonization in Chinese children with moderate to severe atopic dermatitis. Ann Acad Med Singapore. 2005;34: 602-605.
16. Chiang FY, Climo M. Staphylococcus aureus carriage and health care-acquired infection. Curr Infect Dis Rep. 2002;4:498-504.
17. Frenay HM, Vandenbroucke-Grauls CM, Molkenboer MJ, et al. Long-term carriage, and transmission of methicillin-resistant Staphylococcus aureus after discharge from hospital. J Hosp Infect. 1992;22:207-215.
18. Beaujean DJ, Weersink AJ, Blok HE, et al. Determining risk factors for methicillin-resistant Staphylococcus aureus carriage after discharge from hospital. J Hosp Infect. 1999;42:213-218.
19. Hicks NR, Moore EP, Williams EW. Carriage and community treatment of methicillin-resistant Staphylococcus aureus: what happens to colonized patients after discharge? J Hosp Infect. 1991;19: 17-24.
20. Young DM, Harris HW, Charlebois ED, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg. 2004;139:947-951.
21. Chambers HF. Community-associated MRSA-resistance and virulence converge. N Engl J Med. 2005;352:1485-1487.
22. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352: 1436-1444.
23. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin- resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23: 123-127.
24. Kluytmans JS, Wertheim HF. Nasal carriage of Staphylococcus aureus and prevention of nosocomial infections. Infection. 2005;33:3-8.
25. Kampf G, Jarosch R, Ruden H. Limited effectiveness of Chlorhexidine based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect. 1998;38:297-303.
26. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol. 1992;31:1-9.
27. Mulvey MR, MacDougall L, Cholin B, et al, and the Saskatchewan CA-MRSA Study Group. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2005;11:844-850.
28. Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1999;43: 1412-1416.
29. Dryden MS, Dailly S, Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect. 2004;56:283-286.
30. Kanazawa K, Ueda Y. Bactericial activity of Chlorhexidine gluconate against recent clinical isolates of various bacterial species in Japan [in Japanese]. Jpn J Antibiot. 2004;57:449-464.
31. Zhang YH, Liu XY, Zhu LL, et al. Study on the resistance of methicillin-resistant Staphylococcus aureus to iodophor and Chlorhexidine [in Chinese], Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25: 248-250.
32. Block C, Robenshtok E, Simhon A, et al. Evaluation of Chlorhexidine and povidone iodine activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis using a surface test. J Hosp Infect. 2000;46:147-152.
33. Suller MT, Russell AD. Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. J Hosp Infect. 1999;42:281-291.
34. Suzuki J, Komatsuzawa H, Kozai K, et al. In vitro susceptibility of Staphylococcus aureus including MRSA to four disinfectants. ASDC J Dent Child. 1997;64:260-263.
35. Webster J. Handwashing in a neonatal intensive care nursery: product acceptability and effectiveness of Chlorhexidine gluconate 4% and triclosan 1%. J Hosp Infect. 1992;21:137-141.
36. Brenwald NP, Fraise AP. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect. 2003;55:141-144.
37. Bamber AI, Neal TJ. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J Hosp Infect. 1999;41: 107-109.